Home › Psoriasis › Indiana › Indianapolis
Psoriasis clinical trials in Indianapolis, IN
3 studies for Psoriasis are looking for participants at sites in and around Indianapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
RecruitingPhase 3
- Vanda Investigational Site, Indianapolis
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
RecruitingPhase 4
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
- The Indiana Clinical Trials Center, PC, Plainfield · 14 mi away
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RecruitingPhase 3
- Dawes Fretzin Clinical Research Group, LLC, Indianapolis
About Psoriasis
Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. Some people also get psoriasis arthritis.
More about Psoriasis on MedlinePlus
Psoriasis trials in other cities
- Trenton, NJ7 studies
- Cleveland, OH6 studies
- Newton, MA6 studies
- San Antonio, TX5 studies
- Fremont, CA5 studies
- Philadelphia, PA5 studies
- New York City, NY5 studies
- Miami, FL4 studies
- Birmingham, AL4 studies
- Huntington Beach, CA4 studies
- Rochester, NY3 studies
- Los Angeles, CA3 studies
Other studies in Indianapolis
- Non-Small Cell Lung Cancer32 studies
- Cancer (all types)25 studies
- Heart Failure23 studies
- Breast Cancer20 studies
- Obesity20 studies
- Metastatic Cancer19 studies
- Colorectal Cancer18 studies
- Ovarian Cancer17 studies
- Lung Cancer16 studies
- Cardiovascular Disease15 studies
- Endometrial Cancer15 studies
- Alzheimer's Disease14 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.